【摘要】 目的观察白介素—2合并生脉注射液治疗肝癌栓塞化疗后近期疗效、生存率及免疫功能变化等临床指标.方法 采用已确诊的原发性及转移性肝癌144例,随机分为治疗组及对照组各72例,治疗组在采用肝癌栓塞化疗后即用白介素—220万U肌注,5%GS250ml+生脉注射液40ml静脉滴注,1/日,10～15天为1疗程.对照组仅作栓塞化疗,两组病人行栓塞化疗2～6次不等,间隔时间视病情而定.结果治疗组有效率（CR+PR）为 84.7%（61/72）,明显高于对照组（58.3%,42/72）;治疗组1年、2年、3年生存率分别为80.5%、66.7%、35.4%,中位生存期为18个月,而对照组分别为47.2%、31.9%.13.8%,中位生存期为10个月,两组比较有非常显著性差异（P<001）;自然杀伤细胞（NK）活性、T细胞亚群（CD₃、CD₄、CD₈、CD₄/CD₈）数值,在治疗组明显提高,对照组下降,两组有显著差异性（p<005）.结论生脉注射液联合白介素—2治疗肝癌栓塞化疗在有效率、生存率、中位生存期、免疫指标均较单纯塞栓化疗为高,是治疗中晚期肝癌较理想的方法.更多还原

【Abstract】 [Abstract] Objective To observe the effects of SIL- II and Shenmai injection for the treatment of hep-acarcinoma after chemotherapeutic embolization.Methods 144 cases of primary and metastatic hepacarcinoma were selected,and 72 cases served as therapeutic group treated with SIL- II and Shenmai injection,the other cases sered as control group given only chemotherapy and embolism .Results The effective rate of the treating group (CR + PR) was 84.7% (61/72),which was much higher than the control group (58.3%, 42/72) .The survival rate of one ,two and three years was 80.5% , 66.7% and 35.4% individually in the treating group.The midsurvival rate was 18 months.But they were 47.2% , 31.9% and 13.8% in the control group and the midsurvival rate was 10 months. Comparing these, the two groups had significant difference(P <0.0l) .The activity of NK, CD3, CD4, CD8 and CD4/CD8 improved in the treating group after treatment .They descended in the coutrol group with significant difference(P < 0.05) .Conclusion Shenmai injection and SIL-II improved effective rate, survival rate, midsurvival rate and immunologic function in the treating liver cancer after chemotherapy combined with embolism .So it was an ideal method to treat medium and late stage liver cancer.更多还原